Publications

Here you can find links to publications connected to the K.G. Jebsen Colorectal Cancer Research Centre.

Berg et al. 2020. Genomic and prognostic heterogeneity among RAS/BRAFV600E /TP53 co-mutated resectable colorectal liver metastases. Mol Oncol [Epub ahead of print]
Flatin et al. 2020. Multiregional assessment of CIMP in primary colorectal cancers: phenotype concordance but marker variability. Int J Cancer [Epub ahead of print]
Pilleron et al. 2020. Age disparities in stage-specific colon cancer survival across seven countries: an ICBP SURVMARK-2 population-based study. Int J Cancer [Epub ahead of print]
Bergsland et al. 2020. Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open 5(6): e001040
Smeby et al. 2020. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 59: 102923
Eilertsen et al. 2020. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. 469: 246-255
Araghi et al. 2020. Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut gutjnl-2020-320625
Lopes et al. 2020. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer 23: 811-823
Bruun et al. 2020. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin. Cancer Res. 26: 4107-4119
Brunsell et al. 2020. High concordance and negative prognostic impact of RAS/BRAF/PIK3CA mutations in multiple resected colorectal liver metastases. Clin. Colorectal Cancer 19: e26-e47
Dahl et al. 2020. Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta Oncol. 59: 1016-1023
Frydenberg et al. 2020. Chemotherapy during pregnancy for advanced colon cancer: A case report. Clin. Colorectal Cancer. 19: 141-144
Breugom et al. 2020. Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21,196 patients from the Netherlands and Norway. Eur. J. Surg. Oncol. 46: 1167-1173
Al-Haidari et al. 2020. Re-irradiation for recurrent rectal cancer – a single-center experience. Acta Oncol. 59: 534-540
Skrede et al. 2020. Deep learning for prediction of colorectal cancer outcome: A discovery and validation study. Lancet 395: 350-360
Röhrl et al. 2020. High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy: A prospective longitudinal study. Eur. J. Oncol. Nurs. 44: 101679
Joranger et al. 2020. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. Eur. J. Health Econ. 21: 321-334
Guren M 2019. The global challenge of colorectal cancer. Lancet Gastroenterol. Hepatol. 4: 894-895
Hamfjord et al. 2019. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Ann. Oncol. 30: 1088-1095
Araghi et al. 2019. Changes in colorectal cancer incidence in seven high-income countries: A population-based study. Lancet Gastroenetrol. Hepatol. 4: 511-518
Sveen et al. 2019. Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Ann. Oncol. 30(11): 1682-1685
Miranda et al. 2019. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. PNAS 116(18): 9020-9029
Burocziova et al. 2019. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death. Dis. 10(11): 818
Lopes et al. 2019. Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Lab. Invest. 100: 120-134
Dienstmann et al. 2019. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Ann. Oncol. 30(10): 1622-1629
Totland et al. 2019. Regulation of gap junction intercellular communication by connexin ubiquitination: physiological and pathophysiological implications. Cell. Mol. Life Sci. 77: 573-591
Eide et al. 2019. Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties. Int. J. Cancer 144(11): 2843-2853
Glaire et al. 2019. Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. Br. J. Cancer 121: 474-482
Brunsell et al. 2019. Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. Eur. J. Surg. Oncol. 45: 2340-2346
Berg et al. 2019. Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene 38: 6109-6122
Sveen A, Kopetz S, Lothe RA. 2019. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat. Rev. Clin. Oncol. 17: 11-32
Marcuello et al. 2019. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Asp. Med. 69: 107-122
Smeby et al. 2019. Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis 8(6): 35
Guren et al., 2019. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin. Colorectal Cancer, 18: e96-e103
Kryeziu et al., 2019. Combination therapies with HSP90 inhibitors against colorectal cancer. BBA Reviews on Cancer, 1871(2): 240-247
Eilertsen IA et al., 2019. Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer. Int J Cancer, 144(4): 841-847
Røsok et al., 2019. Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver-metastases and small future liver remnants; a translational substudy of the LIGRO-RCT. HPB (Oxford), 21: 1017-1023
Röhrl et al., 2019. Symptoms during chemotherapy in colorectal cancer patients. Support Care Cancer, 27: 3007-3017
Aasen et al., 2019. Connexins in cancer: bridging the gap to the clinic. Oncogene 38: 4429-4451
Rusten et al., 2019. Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors. Br J Radiol, 92: 20181006
Battersby et al., and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery. Colorectal Dis, Suppl 6: 58-68
Bhangu et al., and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesorectal excision (TaTME). Colorectal Dis, Suppl 6: 33-46
Glasbey et al and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. The impact of conversion on the risk of major complication following laparoscopic colonic surgery: an international, multicentre prospective audit. Colorectal Dis, Suppl 6: 69-89
Glasbey et al and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. Association of mechanical bowel preparation with oral antibiotics and anastomotic leak following left sided colorectal resection: an international, multi-centre, prospective audit. Colorectal Dis, Suppl 6: 15-32
Sánchez-Guillén et al and 2017 European Society of Coloproctology (ESCP) collaborating group, 2018. Safety of primary anastomosis following emergency left sided colorectal resection: an international, multi-centre prospective audit. Colorectal Dis, Suppl 6: 47-57
Gleditsch et al., 2018. Surgical options and trends in treating rectal prolapse: long-term results in a 19-year follow-up study. Langenbecks Arch Surg, 403(8): 991-998
Benitez Majano et al., 2019. Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. Lancet Oncology 20: 74–87
Thomsen et al., 2018. Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. Br J Cancer 118(12):1609-1616
Mezheyeuski et al., 2018. Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. Virchows Arch, 472(3): 395-405
Eide et al., 2018. Long non-coding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties. Int J Cancer, 144: 2843-2853
Claassen YHM et al., 2018. Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison. Br J Cancer, 119, 517–522
Ommundsen N et al., 2018. Post-discharge complications in frail older patients after surgery for colorectal cancer. Eur J Surg Oncol, 44: 1542-1547
Bretthauer M et al., 2018. Uterine morcellation and survival in uterine sarcomas. Eur J Cancer, 101: 62-8
Pedersen IB et al., 2018. Polypectomy techniques among gastroenterologists in Norway – a nationwide survey. Endosc Int Open, 6(7): E812-20
Høland M et al., 2018. Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. Mod Pathol, [Epub ahead of print]
Bruun J et al., 2018, Prognostic, predictive and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Mol Oncol, [Epub ahead of print]
Vedeld HM et al., 2018. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin Epigenetics, 10: 70
Vermeer NCA et al., 2018. Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison. Oncologist, [Epub ahead of print]
Smeby J et al., 2018. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Ann Oncol, 29(5): 1227-34
Pharo HD et al., 2018. A robust internal control for high-precision DNA methylation analyses by droplet digital PCR. Clin Epigenetics, 10: 24
Oltedal S et al., 2018. The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer. Transl Oncol, 11(2): 436-43
Holme Ø et al., 2018. Endoscopy assistants influence the quality of colonoscopy.Endoscopy [Epub ahead of print]
Danielsen HE et al., 2018. Prognostic markers for colorectal cancer: estimating ploidy and stroma. Ann Oncol, 29(3): 616-23
Vedeld HM et al., 2018. Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives. Semin Cancer Biol, 51: 36-49
Sveen A et al., 2018. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clin Cancer Res, 24(4): 794-806
Berg KCG et al., 2017. Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies. Mol Cancer, 16(1): 116
Dienstmann R et al., 2017. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol, 28(5): 1023-31
Eide PW et al., 2017. CMScaller: An R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Sci Rep, 7(1): 16618
Øines M et al., 2017. Epidemiology and risk factors of colorectal polyps. Best Pract Res Clin Gastroenterol, 31(4): 419-24
Emilsson L et al., 2017. Colorectal cancer death after adenoma removal in Scandinavia. Scand J Gastroenterol, 52(12): 1377-84
Byskov CS et al., 2017. The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer. Physics and Imaging in Radiation Oncology, 3: 43–48
Rusten E et al., 2017. Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography. Radiat Oncol, 12(1): 147
Lind GE et al., 2017. Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients. Clin Epigenetics, 9: 97
Landskron J et al. 2017. C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLoS One. 2017 Jul 31;12(7):e0182030.
Ommundsen N et al. 2017. Preoperative geriatric assessment and tailored interventions in frail older patients with colorectal cancer. A randomised controlled trial. Colorectal Dis. 2017 Jun 26. [Epub ahead of print]
Lind GE et al. 2017. Details matter: the role of genomic location and assay standardization in DNA methylation analyses. Epigenomics. 2017 Jul;9(7):933-935.
Garborg K et al. 2017. Quality Indicators in Colonoscopy. Curr Treat Options Gastroenterol. 2017 Jul 12. [Epub ahead of print]
Totland MZ et al. 2017. The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin43 to promote loss of gap junctions. J Cell Sci. 2017 Sep 1;130(17):2867-2882.
Guren TK et al. 2017. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. Br J Cancer. 2017 May 9;116(10):1271-1278.
Sclafani F et al. 2017. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial. Int J Cancer. 2017 Jan 15;140(2):431-439.
Hoff G et al. 2017. Cecum intubation rate as quality indicator in clinical versus screening colonoscopy. Endosc Int Open. 2017 Jun;5(6):E489-E495.
Holme Ø et al. 2017. Authors' reply to Doherty and Hawkins. BMJ. 2017 Mar 10;356:j1267.
Kaminski MF et al. 2017. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2017 Apr;49(4):378-397.
Bretthauer M et al. 2017. America, We Are Confused: The Updated U.S. Preventive Services Task Force Recommendation on Colorectal Cancer Screening. Ann Intern Med. 2017 Jan 17;166(2):139-140.
Astrup GL et al. 2017. Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol. 2017 Mar;56(3):462-470.
Berg KCG et al. 2017. Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies. Mol Cancer. 2017 Jul 6;16(1):116.
Vedeld HM et al. 2017. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. Int J Cancer. 2017 Sep 1;141(5):967-976.
Sveen A et al. 2017. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Med. 2017 May 24;9(1):46.
Thomsen M et al. 2017. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. Eur J Cancer. 2017 Aug;81:26-35.
Åsli LM et al. 2017. Preoperative chemoradiotherapy for rectal cancer and impact on outcomes – A population-based study. Radiother Oncol. 2017 Jun;123(3):446-453.
Hoff G et al. 2017. Patient-reported adverse events after colonoscopy in Norway. Endoscopy. 2017 Aug;49(8):745-753.
Labori KJ et al. 2017. Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short term surgical outcomes, overall and recurrence free survivals. Colorectal Dis. 2017 Aug;19(8):731-738.
Dienstmann R et al. 2017. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 May 1;28(5):1023-1031.
Stornes T et al. 2016. National Early Rectal Cancer Treatment Revisited. Dis Colon Rectum. 2016 Jul;59(7):623-9.
Boye K et al. 2016. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Med. 2016 Aug;5(8):1840-9.
Gleditsch D et al. 2016. Managing Malignant Colorectal Obstruction with Self-Expanding Stents. A Closer Look at Bowel Perforations and Failed Procedures. J Gastrointest Surg. 2016 Sep;20(9):1643-9.
Løberg M et al. 2016. Commentary: "Randomize, Then Consent" or "Consent, Then Randomize"?: Revitalizing the Issue of Preconsent Randomization. Epidemiology. 2016 May;27(3):393-4.
Holme Ø et al. 2016. Methodological considerations for surveillance in GI practice. Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):867-878.
Adami HO et al. 2017. Are rapidly growing cancers more lethal? Eur J Cancer. 2017 Feb;72:210-214. Epub 2016 Dec 30.
Emilsson L et al. 2017. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther. 2017 Jan;45(2):193-204. Epub 2016 Nov 17.
Kaminski MF et al. 2016. Cancer surveillance in gastroenterology practice. Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):853-854.
Gjøstein DK et al. 2016. Incentives and participation in a medical survey. Tidsskr Nor Laegeforen. 2016 Jul 5;136(12-13):1082-7.
Rees CJ et al. 2016. Expert opinions and scientific evidence for colonoscopy key performance indicators. Gut. 2016 Dec;65(12):2045-2060.
Garborg K et al. 2017. Gradual stiffness versus magnetic imaging-guided variable stiffness colonoscopes: A randomized noninferiority trial. United European Gastroenterology Journal 2017, Vol. 5(1) 128–133.
Jørgensen KJ et al. 2016. Overview of guidelines on breast screening: Why recommendations differ and what to do about it. Breast. 2017 Feb;31:261-269.
Rutter MD et al. 2016. The European Society of Gastrointestinal Endoscopy Quality Improvement Initiative: developing performance measures. United European Gastroenterol J. 2016 Feb;4(1):30-41.
Rees CJ et al. 2016. European Society of Gastrointestinal Endoscopy – Establishing the key unanswered research questions within gastrointestinal endoscopy. Endoscopy. 2016 Oct;48(10):884-891.
Bretthauer M et al. 2016. Requirements and standards facilitating quality improvement for reporting systems in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2016 Mar;48(3):291-4.
Bisschops R et al. 2016. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2016 Sep;48(9):843-64.
Bisschops R et al. 2016. Performance measures for upper gastrointestinal endoscopy: A European Society of Gastrointestinal Endoscopy quality improvement initiative. United European Gastroenterol J. 2016 Oct;4(5):629-656.
Berstad P et al. 2016. Lifestyle changes at middle age and mortality: a population-based prospective cohort study. J Epidemiol Community Health. 2017 Jan;71(1):59-66. Epub 2016 Jun 16.
Pharo HD et al. 2016. Experimental factors affecting the robustness of DNA methylation analysis. Sci Rep. 2016 Sep 27;6:33936.
Fykerud TA et al. 2016. Mitotic cells form actin-based bridges with adjacent cells to provide intercellular communication during rounding. Cell Cycle. 2016 Nov;15(21):2943-2957.
Mezheyeuski A et al. 2016. Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. Oncotarget. 2016 Jul 5;7(27):41948-41958.
Tarpgaard LS et al. 2016. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. Oncotarget. 2016 Sep 13;7(37):59441-59457.
Thomsen M et al. 2016. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget. 2016 Nov 15;7(46):75013-75022.
Røhrl K et al. 2016. No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy. J Pain Symptom Manage. 2016 Oct;52(4):539-547.
Holme Ø et al. 2017. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ. 2017 Jan 13;356:i6673.
Glimelius B et al. 2016. Two countries – Two treatment strategies for rectal cancer. Radiother Oncol. 2016 Dec;121(3):357-363.
García-Albéniz X et al. 2016. Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study. Ann Intern Med. 2017 Jan 3;166(1):18-26.
Domingo E et al. 2016. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology & Hepatology. Volume 1, No. 3, p207–216, November 2016
Sveen A et al. 2016. Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. PLoS Genet. 2016 Jul 29;12(7):e1006225.
Cameron MG et al. 2016. Palliative pelvic radiotherapy for symptomatic rectal cancer – a prospective multicenter study. Acta Oncol. 2016 Dec;55(12):1400-1407.
Rønning B et al. 2016. Quality of life in older and frail patients after surgery for colorectal cancer – A follow-up study. J Geriatr Oncol. 2016 May;7(3):195-200.
Holme Ø et al. 2016. Pain and sedation during colonoscopy – a never ending story. Endosc Int Open. 2016 May;4(5):E538-9.
Bretthauer M et al. 2016. Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial. JAMA Intern Med. 2016 Jul 1;176(7):894-902.
Garborg K et al. 2016. Cecal intubation failure: Refer or change technique? Gastrointest Endosc. 2016 June;83(6):1245–1247
Jover R et al. 2016. Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy. 2016 Jun;48(6):571-8.
Bretthauer M et al. 2016. Reporting systems in gastrointestinal endoscopy: Requirements and standards facilitating quality improvement: European Society of Gastrointestinal Endoscopy position statement. United European Gastroenterol J. 2016 Apr;4(2):172-6.
Bretthauer M et al. 2016. Who Is for CO2? Slow Adoption of Carbon Dioxide Insufflation in Colonoscopy. Ann Intern Med. 2016 Jul 19;165(2):145-6.
Adami H-O et al. 2016. The continuing uncertainty about cancer risk in inflammatory bowel disease. Gut. 2016 Jun;65(6):889-93.
Cekaite L et al. 2016. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget. 2016 Feb 9;7(6):6476-505.
Hoff AM et al. 2015. Novel RNA variants in colorectal cancers. Oncotarget. 2015 Nov 3;6(34):36587-602.
Tarpgaard LS et al. 2015. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. Int J Cancer. 2015 Nov 15;137(10):2470-7.
Leon O et al. 2015. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015 Dec;51(18):2740-6.
Kjersem JB et al. 2016. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. Pharmacogenomics J. 2016 Jun;16(3):272-9. Epub 2015 Aug 11.
Hassan C et al. 2016. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis. Gut. 2016 May;65(5):806-20. Epub 2015 Feb 13.
Dueland S et al. 2015. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015 May;261(5):956-60.
Bretthauer M et al. 2016. Do's and don'ts in evaluation of endoscopic screening for gastrointestinal cancers. Endoscopy. 2016 Jan;48(1):75-80.
Sveen A et al. 2016. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016 May 12;35(19):2413-27.
Guren MG et al. 2015. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncol. 2015 Apr 30:1-9.
Walters S et al. 2015. Is England closing the international gap in cancer survival? Br J Cancer. 2015 Sep 1;113(5):848-60.
Cameron MG et al. 2015. Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study. Radiother Oncol. 2015 Jun;115(3):314-20.
Vedeld HM et al. 2015. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. Int J Cancer. 2015 Feb 15;136(4):844-53.
Bretthauer M et al. 2015. More adenomas – less cancer? Advanced imaging in colonoscopy. Endoscopy. 2015 May;47(5):396-7.
Robertson DJ et al. 2015. Effectiveness, training and quality assurance of colonoscopy screening for colorectal cancer. Gut. 2015 Jun;64(6):982-990.
Kaminski MF et al. 2016. Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial. Gut. 2016 Apr;65(4):616-24.
Garborg K et al. 2015. Water exchange versus carbon dioxide insufflation in unsedated colonoscopy: a multicenter randomized controlled trial. Endoscopy. 2015 Mar;47(3):192-9.
Holme Ø et al. 2015. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut. 2015 Jun;64(6):929-36.
Spada C et al. 2015. Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline. Eur Radiol. 2015 Feb;25(2):331-45.
Bruun J et al. 2015. Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer. Clin Cancer Res. 2015 Aug 15;21(16):3759-70.
Joranger P et al. 2015. Modeling and validating the cost and clinical pathway of colorectal cancer. Med Decis Making. 35(2):255-65.
Berstad P et al. 2015. Long-term lifestyle changes after colorectal cancer screening: randomised controlled trial. Gut. 2015 Aug;64(8):1268-76.
Dueland S et al. 2015. Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy? Ann Surg Oncol. 2015 Jul;22(7):2195-200.
Gustavsson B et al. 2015. A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer. Clin Colorectal Cancer. 14(1):1-10.
Guren MG et al. 2014. Reirradiation of locally recurrent rectal cancer: A systematic review. Radiother Oncol. 113(2): 151–157.
Danielsen SA, Eide PW et al. 2015. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 2015 Jan;1855(1):104-21.
Leon O et al. 2014. Anal carcinoma – Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiother Oncol. 113(3):352-8.
Asli LM et al. 2014. Utilization of radiation therapy in Norway after the implementation of the national cancer plan – a national, population-based study. Int J Radiat Oncol Biol Phys. 90(3):707-14.
Holme Ø et al. 2014. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 312(6):606-15.
Ommundsen N et al. 2014. Frailty is an independent predictor of survival in older patients with colorectal cancer. Oncologist. 19(12):1268-75.
Bruun J et al. 2014. Prognostic significance of beta-catenin, E-cadherin, and SOX9 in colorectal cancer: Results from a large population-representative series. Front. Oncol. 4: 118.
Løberg M et al. 2014. Long-term colorectal-cancer mortality after adenoma removal. N. Engl. J. Med. 371(9): 799-807.
Løvf M et al. 2014. A novel transcript, VNN1-AB, as a biomarker for colorectal cancer. Int. J. Cancer 135(9): 2077-2084.
Kjersem JB et al. 2014. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC Cancer 14: 340.